Natera Inc Asset Resilience Ratio
Natera Inc asset resilience ratio. Natera Inc (NTRA) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Natera Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Natera Inc (2013–2025)
Asset resilience ratio of Natera Inc from 2013 to 2025. This chart shows how Natera Inc's Asset Resilience Ratio has changed over time. Read NTRA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Natera Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Natera Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Natera Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Natera Inc Industry Peers by Asset Resilience Ratio
Compare Natera Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Hangzhou Tigermed Consulting
SHE:300347 |
Diagnostics & Research | 0.11% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Natera Inc Asset Resilience Ratio by Year (2013–2025)
Natera Inc asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Natera Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $2.51 Billion | -- |
| 2024-12-31 | 1.37% | $22.69 Million | $1.66 Billion | -15.06pp |
| 2023-12-31 | 16.43% | $236.88 Million | $1.44 Billion | -14.57pp |
| 2022-12-31 | 31.00% | $432.30 Million | $1.39 Billion | -36.12pp |
| 2021-12-31 | 67.12% | $829.90 Million | $1.24 Billion | -6.76pp |
| 2020-12-31 | 73.87% | $688.61 Million | $932.15 Million | +8.81pp |
| 2019-12-31 | 65.06% | $379.06 Million | $582.66 Million | +24.99pp |
| 2018-12-31 | 40.07% | $107.46 Million | $268.17 Million | -9.43pp |
| 2017-12-31 | 49.51% | $106.25 Million | $214.61 Million | -12.61pp |
| 2016-12-31 | 62.11% | $130.86 Million | $210.68 Million | -13.89pp |
| 2015-12-31 | 76.00% | $201.59 Million | $265.24 Million | +75.59pp |
| 2014-12-31 | 0.41% | $503.00K | $123.62 Million | +0.16pp |
| 2013-12-31 | 0.25% | $150.00K | $59.72 Million | -- |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehe… Read more